DAPAGLIFLOZIN PROPANEDIOL ANHYDROUS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H25ClO6.C3H8O2
Molecular Weight	484.967
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of DAPAGLIFLOZIN PROPANEDIOL ANHYDROUS

Structure Search

SMILES

C[C@H](O)CO.CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)C=C1

InChI

InChIKey=VYOCLVRXZCRBML-XMODHJQGSA-N

InChI=1S/C21H25ClO6.C3H8O2/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21;1-3(5)2-4/h3-8,10,17-21,23-26H,2,9,11H2,1H3;3-5H,2H2,1H3/t17-,18-,19+,20-,21+;3-/m10/s1

HIDE SMILES / InChI

Molecular Formula	C3H8O2
Molecular Weight	76.0944
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	C21H25ClO6
Molecular Weight	408.873
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/27042132

Dapagliflozin (trade name Farxiga in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, developed by Bristol-Myers Squibb in partnership with AstraZeneca. Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/glucose cotransporter 2 25 Target ID: CHEMBL3884 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/23657801	Inhibitor 8504		1.16 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Type 2 diabetes mellitus 262 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf	Primary		Approved 8583	FARXIGA Approved Use FARXIGA (dapagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Launch Date 2014

C_max

Value	Dose	Analyte	Population
118 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
154 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
24.8 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
24.6 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
48.4 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
49 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
116 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED
119 ng/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED

AUC

Value	Dose	Analyte	Population
427 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
418 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
658 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
612 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	10 mg single, oral dose: 10 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
101 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
92.3 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
105 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
95.8 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	2.5 mg single, oral dose: 2.5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
199 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
189 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: unhealthy age: Children sex: food status:
232 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
208 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01525238	5 mg single, oral dose: 5 mg route of administration: oral experiment type: single co-administered:	DAPAGLIFLOZIN 3-O-GLUCURONIDE plasma	Homo sapiens population: unhealthy age: Children sex: food status:
368 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED
506 ng × h/mL REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:	DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
3 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED
15.77 h REVIEW https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf	10 mg 1 times / day steady-state, oral dose: 10 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		DAPAGLIFLOZIN plasma	Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: FASTED

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252 substrate 1946	inhibitor 2438 substrate 1193	inhibitor 2507 substrate 1388

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP 110 CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C19 2057 CYP2C8 1057 OAT1 725 OAT3 747 OATP1B1 1079 OATP1B3 961 OCT2 779 P-gp 1741	CYP 303 CYP1A1 389 CYP1A2 1197 CYP2A6 626 CYP2E1 729 CYP3A5 446 OAT1 395 OAT3 391 OATP1B1 503 OATP1B3 435 OCT2 434 P-gp 2052 UGT1A9 423	CYP1A2 832 CYP2B6 669 CYP3A4/5 133 PXR 10

Drug as perpetrator

Target	Modality	Activity	Clinical evidence
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no [IC50 >45 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no [IC50 >45 uM]
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no [IC50 >45 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no [IC50 >45 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no [IC50 >45 uM]
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67	no [IC50 >45 uM]	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67	no [IC50 >45 uM]	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67	no [IC50 >45 uM]	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 67
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67	no [IC50 >57.6 uM]	no (co-administration study) Comment: dapagliflozin does not demonstrate any ability to inhibit P-gp mediated efflux of digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67
CYP1A2 2333	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no
CYP2B6 1160	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no
CYP3A4/5 357	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64.0	no
PXR 51	inducer 1966 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	no
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67	no	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67
CYP 150	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 91.0	weak [IC50 >45 uM]
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67	yes [IC50 33 uM]	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 64, 67
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	yes [IC50 69 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	yes [IC50 8 uM]

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 67.0	minor
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	no
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	no
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	no	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted from clinical pharmacology review p67 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 68.0	weak
CYP1A2 1197	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	yes
CYP2A6 626	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	yes
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	yes
CYP2E1 729	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	yes
CYP3A5 446	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63.0	yes
CYP1A1 389	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65	yes	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65
CYP2C9 1193	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65	yes	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65	yes	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 63, 65
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0	yes	no (co-administration study) Comment: no clinically meaningful drug-drug interaction observed in the all the DDI studies conducted from clinical pharmacology review p67 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000PharmR.pdf Page: 29.0
UGT1A9 423	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 65.0	yes	unlikely (co-administration study) Comment: coadministration of mefenamic acid showed slight increase in dapagliflozin exposure; the increase in exposure does not warrant any dose adjustment Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000ClinPharmR.pdf Page: 65.0

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:85078	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:85078
ChemicalBook	CB91011730	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB91011730
eMolecules	32278060	https://www.emolecules.com/cgi-bin/more?vid=32278060
MolPort	MolPort-009-682-875	https://www.molport.com/shop/molecule-link/MolPort-009-682-875
Selleck Chemicals	Dapagliflozin	http://www.selleckchem.com/products/Dapagliflozin.html
ZINC	ZINC000003819138	http://zinc15.docking.org/substances/ZINC000003819138

PubMed

Title	Date	PubMed
Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors.	2011-04-28	21449606
Discovery of non-glucoside SGLT2 inhibitors.	2011-04-15	21398124
Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.	2011-01-13	21128592
A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors.	2010-12	22558567
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.	2010-12	22127746
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.	2010-12	22127745
Validated LC-MS/MS methods for the determination of dapagliflozin, a sodium-glucose co-transporter 2 inhibitor in normal and ZDF rat plasma.	2010-12	21110743
Dapagliflozin: more than just another oral glucose-lowering agent?	2010-12	21105857
The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats.	2010-11	20880347
Diabetes: Dapagliflozin: an insulin-independent, therapeutic option for type 2 diabetes mellitus.	2010-10	21080534
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.	2010-10	20566676
Gateways to clinical trials.	2010-09-21	20852754
Gateways to clinical trials.	2010-09	21069103
Synthesis of pyridazine and thiazole analogs as SGLT2 inhibitors.	2010-08-15	20637636
(5-Bromo-2-methyl-phen-yl)(4-eth-oxy-phen-yl)methanone.	2010-07-17	21588347
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.	2010-06-26	20609968
Dapagliflozin, an SGLT2 inhibitor, for diabetes.	2010-06-26	20609956
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight.	2010-06	20518806
Neuropathy, retinopathy, and glucose-lowering treatments.	2010-06	20508223
Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.	2010-03-05	20205482
In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans.	2010-03	19996149
Dapagliflozin: BMS 512148; BMS-512148.	2010	20509715
Gateways to clinical trials.	2009-12	20140276
Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.	2009-12	19943222
(5-Bromo-2-chloro-phen-yl)(4-ethoxy-phen-yl)methanone.	2009-11-14	21578801
Gateways to clinical trials.	2009-10	19967103
Dapagliflozin: where does it fit in the treatment of type 2 diabetes?	2009-10	19735212
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.	2009-09	19528367
Dapagliflozin for the treatment of type 2 diabetes.	2009-07	19584379
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.	2009-06	19357717
Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.	2009-05	19129749
Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects.	2009-05	19129748
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes.	2009-04	19114612
Gateways to clinical trials.	2009-03	19455266
Diabetes treatment.	2009-03	19246581
Dapagliflozin: an emerging treatment option in type 2 diabetes.	2009-03	19243283
Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.	2008-09	18996802
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.	2008-06	18356408
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.	2008-03-13	18260618
Molecule of the month. Dapagliflozin.	2007-12	18301798

Patents

Sample Use Guides

In Vivo Use Guide

The recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Dose can be increased to 10 mg once daily in patients tolerating FARXIGA who require additional glycemic control.

Route of Administration: Oral

In Vitro Use Guide

The IC50 values of dapagliflozin for hSGLT2 and hSGLT1 determined using 1-NBDG were 1.86 nM and 880 nM

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:40:39 GMT 2025` Edited by `admin` on `Mon Mar 31 18:40:39 GMT 2025`
Record UNII	4AKF24FA4C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(2S,3R,4R,5S,6R)-2-(4-CHLORO-3-(4-ETHOXYBENZYL)PHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO- 2H-PYRAN-3,4,5-TRIOL, (2S)-PROPANE-1,2-DIOL (1:1)

Preferred Name

English

DAPAGLIFLOZIN PROPANEDIOL ANHYDROUS

Common Name

English

D-GLUCITOL, 1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-ETHOXYPHENYL)METHYL)PHENYL)-, (1S)-, COMPD. WITH (2S)-1,2-PROPANEDIOL (1:1)

Common Name

English

DAPAGLIFLOZIN S-PROPYLENE GLYCOL

Common Name

English

Code System Code Type Description

FDA UNII

4AKF24FA4C